Skip to main content

Client News

InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting

8th March 2022

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

8th March 2022

AiCuris erhält NRW-Förderung von insgesamt EUR 5,9 Mio. für die Entwicklung seines Corona-Virus-Programms zur Vorbeugung schwerer Symptome bei SARS-CoV-2-Infektionen

3rd March 2022

RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19

1st March 2022

InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa

28th February 2022

Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment

28th February 2022

Adocia announces 2021 fourth quarter financial results

23rd February 2022

dievini and related parties underline their strong commitment as shareholders of CureVac N.V. and do no longer plan to sell shares to the public

22nd February 2022

Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients

22nd February 2022

Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

22nd February 2022